A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC.

ubenimex (DFP-14323) - Delta-Fly Pharma

Gilotrif (afatinib) - Boehringer Ingelheim

http://www.ncbi.nlm.nih.gov/pubmed/42688362

Cheng-Long Huang; Hiroshige Yoshioka; Hirotaka Matsumoto; Hiroyasu Kaneda; Kouji Yamamoto; Masahide Mori; Motohiro Tamiya; Nobuyuki Katakami; Toshihide Yokoyama

Sep 4, 2026